---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-096923"
form_type: "8-K/A"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2025-07-18T23:59:59+00:00"
generated_at: "2026-05-18T05:50:47.280452+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics amends 8-K to disclose up to 41.4M shares issuable under SEPA with YA II PN

## Summary
- Maximum shares convertible from $15M promissory notes: 36,945,812 shares at $0.406/share.
- Additional maximum shares from Commitment Amount: 4,424,778 shares at $2.26/share.
- Agreement with YA II PN, Ltd. was previously disclosed on Dec 20, 2024; amendment adds share counts.
- Conversion price subject to anti-dilution adjustments; shares unregistered under Securities Act.

## SEC filing metadata
- accession: 0000950170-25-096923
- form_type: 8-K/A
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2025-07-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000095017025096923/0000950170-25-096923-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000095017025096923/fblg-20241220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-096923
- JSON: https://secwatch.observer/filing/0000950170-25-096923.json
- Plain text: https://secwatch.observer/filing/0000950170-25-096923.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.